RxDoctor Payments Data

Surekha Bandlamuri, MD

Internal Medicine · Tucson, AZNPI 1487672564

Payments from drug & device makers

$16,945in general payments, 2019–2025

Across 805 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • AstraZeneca$2K
  • GSK$2K
  • Amgen$1K
  • Bayer$1K
  • Boehringer Ingelheim$1K
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$16,71099%
  • Education$2351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,945 in reported general payments places this provider in the 95th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$197,641
Medicare patients
231
Services billed
8,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide125$219,387
ProliaDenosumab64$107,405
JardianceEmpagliflozin113$100,584
EliquisApixaban92$90,659
OzempicSemaglutide40$56,272
JanuviaSitagliptin Phosphate29$44,966
MyrbetriqMirabegron46$43,727
FarxigaDapagliflozin Propanediol32$38,899
LinzessLinaclotide38$29,536
TrulicityDulaglutide23$27,582
MounjaroTirzepatide11$21,986
XareltoRivaroxaban11$18,325
EntrestoSacubitril/Valsartan14$17,174
ShingrixVaricella-Zoster Ge/As01b/Pf77$16,985
Fluticasone-SalmeterolFluticasone Propion/Salmeterol86$15,819

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$2,607$275,659165 claims
AmgenProlia$1,306$107,40564 claims
Boehringer IngelheimJardiance$1,075$100,584113 claims
PfizerEliquis$341$90,65992 claims
MerckJanuvia, Janumet, Belsomra$378$69,82954 claims
AstraZenecaFarxiga, Symbicort$1,946$50,08462 claims
Lilly USA, LLCTrulicity, Mounjaro$752$49,56834 claims
Astellas Pharma US IncMyrbetriq$247$43,72746 claims
AbbVieLinzess, Synthroid$867$33,85885 claims
GSKShingrix, Trelegy Ellipta$1,625$32,26096 claims
Johnson & JohnsonXarelto$135$18,32511 claims
NovartisEntresto$641$17,17414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →